Last June 8th, our co-founder Pr. Dr. Carel Hoyng attended to an important meeting with the FDA as a member of the executive board of the Foundation Fighting for Blindness. Main topic was how to design better clinical trials for promising new treatments in IRD. This kind of meetings emphasize how important it is to join forces in developing new treatments for Inherited Retinal Diseases.
The Usher 2A syndrome natural history studies will provide a strong basis to build better clinical trials with solid patient outcome parameters in the near future.
Meetings like this will support collaborating efficiently between top experts worldwide and the regulatory agencies to achieve the ultimate treatment goals for patients.